Sarepta Therapeutics Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Sarepta Therapeutics stock.
View analyst ratings for Sarepta Therapeutics or view top-rated stocks.

13 Wall Street analysts have issued 12 month price targets for Sarepta Therapeutics' shares. Their SRPT stock forecasts range from $74.00 to $155.00. On average, they anticipate Sarepta Therapeutics' stock price to reach $119.25 in the next year. This suggests a possible upside of 58.5% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics or view top-rated stocks among Wall Street analysts.

Sarepta Therapeutics' stock was trading at $90.05 at the beginning of 2022. Since then, SRPT shares have decreased by 16.5% and is now trading at $75.22.
View the best growth stocks for 2022 here.

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Sarepta Therapeutics.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its quarterly earnings results on Wednesday, May, 4th. The biotechnology company reported ($1.20) earnings per share for the quarter, topping the consensus estimate of ($1.35) by $0.15. The biotechnology company had revenue of $210.83 million for the quarter, compared to analyst estimates of $208.25 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 52.06% and a negative net margin of 46.56%. Sarepta Therapeutics's quarterly revenue was up 43.5% on a year-over-year basis. During the same period in the prior year, the business earned ($2.10) EPS.
View Sarepta Therapeutics' earnings history.

Sarepta Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, March, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $880 M-, compared to the consensus revenue estimate of $908.46 million.

15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics' employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Sarepta Therapeutics include Royalty Pharma (RPRX), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), Genmab A/S (GNMSF), Catalent (CTLT), Horizon Therapeutics Public (HZNP), BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Viatris (VTRS), Ono Pharmaceutical (OPHLF) and United Therapeutics (UTHR).
View all of SRPT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.50%), Sands Capital Management LLC (5.47%), Wellington Management Group LLP (3.06%), Bellevue Group AG (1.32%), Farallon Capital Management LLC (1.13%) and Goldman Sachs Group Inc. (1.06%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics.

SRPT stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Victory Capital Management Inc., Zurcher Kantonalbank Zurich Cantonalbank , Goldman Sachs Group Inc., Tekla Capital Management LLC, Renaissance Technologies LLC, JPMorgan Chase & Co., and Simplex Trading LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last two years include Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics or view top insider-selling stocks.

SRPT stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Wellington Management Group LLP, Bank of Montreal Can, Prudential Financial Inc., Assenagon Asset Management S.A., Bellevue Group AG, Allspring Global Investments Holdings LLC, and Farallon Capital Management LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, and Louise Rodino-Klapac.
View insider buying and selling activity for Sarepta Therapeutics or or view top insider-buying stocks.

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRPT stock can currently be purchased for approximately $75.22.

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $6.58 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418.78 million in net income (profit) each year or ($4.24) on an earnings per share basis.

Sarepta Therapeutics employs 840 workers across the globe.

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (857) 242-4000, via email at [email protected], or via fax at 425-354-5038.